Agilent Technologies, Inc. (NYSE:A ) Q3 2024 Earnings Conference Call August 21, 2024 4:30 PM ET Company Participants Conference Call Participants Operator Ladies and gentlemen, welcome to the Agilent Technologies Q3 2024 Earnings Call. My name is Regina and I will be coordinating your call today.
While the top- and bottom-line numbers for Agilent (A) give a sense of how the business performed in the quarter ended July 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Agilent Technologies (A) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.25 per share. This compares to earnings of $1.43 per share a year ago.
Agilent Technologies on Wednesday beat Wall Street estimates for third-quarter profit and revenue, banking on strong demand for its medical tools and equipment used in clinical studies.
Agilent Technologies (A) launches J&W 5Q GC/MS Columns to address the growing demand for modern laboratories.
Beyond analysts' top -and-bottom-line estimates for Agilent (A), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended July 2024.
Agilent (A) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agilent (A) unveils its new ProteoAnalyzer system in a bid to strengthen its Diagnostics and Genomics Group segment.
Agilent Technologies said on Monday it will acquire contract drug manufacturer Biovectra for $925 million to expand its portfolio of services offered to biotech companies and medical researchers.
Intuitive Surgical's game-changing robotic surgical systems should continue fueling considerable growth for the business. UnitedHealth is in an excellent position to benefit from the health insurance industry's long-term growth.
Agilent (A) reported earnings 30 days ago. What's next for the stock?
A, CAR and BGS have been added to the Zacks Rank #5 (Strong Sell) List on June 7, 2024.